Transgene
First patient dosed in Transgene and BioInvent’s phase 1 trial
October 10, 2023Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial
Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …
BioInvent and Transgene announce positive phase 1a solid tumour trial data
May 25, 2023Research and Development BioInvent, Oncology, Transgene, clinical trials, oncology, tumours
Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from a trial studying BT-001 for …
Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate
December 16, 2019Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma
Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …
Transgene terminates oncolytic IO combo trial in advanced liver cancer
August 8, 2019Research and Development Cancer, Transgene, clinical trials, liver cancer, pharma
Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …
Transgene announce key partnership with Merck KGaA and Pfizer
October 12, 2016Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck
Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …
Sanofi in immunotherapy tie-up
March 26, 2013Research and Development, Sales and Marketing Transgene, snaofi
Sanofi has signed a 15-year deal with biopharma company Transgene to produce a platform to help create a range of …
Transgene appoints Nathalie Adda as chief medical officer
September 21, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Nathalie Adda, Transgene
Transgene has announced the appointment of Dr Nathalie Adda as chief medical officer. Responsible for medical and regulatory affairs of …
Roche pulls out of vaccine alliance with Transgene
February 23, 2011Research and Development HPV, HPV vaccine, Roche, TG4001, Transgene, cervical cancer, cervical lesions, human papilloma virus, vaccines
Roche has terminated its license agreement with Transgene for its HPV therapeutic vaccine TG4001. The vaccine is currently being tested …
Transgene acquires rights to cancer vaccine
September 10, 2010Research and Development JX-594, Jennerex, Transgene, cancer vaccine
French biotech company Transgene has acquired rights to commercialise a novel cancer vaccine that is being tested against multiple types …
Lung cancer vaccine poised to begin phase IIb/III trials
September 1, 2010Research and Development NSCLC, TG4010, Transgene, cancer vaccine
French biotech firm Transgene has received positive scientific advice from the EMA for late stage trials of its new lung …
Novartis buys into Transgene’s lung cancer candidate
March 11, 2010Research and Development Novartis, Transgene, immunotherapy, lung cancer
French biotech company Transgene has signed a deal with Novartis for the future development and marketing of its potential lung …
